Skip to main content
Immunovia logo

Immunovia — Investor Relations & Filings

Ticker · IMMNOV ISIN · SE0006091997 LEI · 549300KHWL6KK1XGUO81 ST Human health and social work activities
Open in API
Filings indexed 374 across all filing types
Latest filing 2025-11-28 Share Issue/Capital Cha…
Country SE Sweden
Listing ST IMMNOV

About Immunovia

https://immunovia.com/

Immunovia is a diagnostics company focused on revolutionizing the early detection of pancreatic cancer. Its primary product is the PancreaSure test, a simple blood test designed to detect pancreatic cancer at Stage 1 and 2 with high accuracy. The test is intended for annual surveillance of individuals at elevated risk due to family history or genetic mutations. PancreaSure functions by detecting proteins and other biomarkers indicative of pancreatic cancer growth. The company's mission is to improve survival rates for this highly lethal cancer by enabling diagnosis at its earliest, most treatable stages, offering a convenient alternative to invasive imaging procedures.

Recent filings

Filing Released Lang Actions
Ändring av antalet aktier och röster i Immunovia AB (publ)
Share Issue/Capital Change Classification · 1% confidence The document is an official announcement regarding a change in the total number of shares and votes in Immunovia AB (publ) following a rights issue and a directed share issue. This type of regulatory disclosure, specifically concerning changes in share capital and voting rights, falls under the category of share issues and capital changes.
2025-11-28 Swedish
Change in number of shares and votes in Immunovia AB (publ)
Share Issue/Capital Change Classification · 1% confidence The document explicitly announces a change in the number of shares and votes in Immunovia AB due to a rights issue and a directed issue of shares. This falls under the category of capital changes and share issuance announcements. According to the provided definitions, 'SHA' is the appropriate code for announcements regarding new share issues or capital changes.
2025-11-28 English
Interim / Quarterly Report 2025
Interim / Quarterly Report Classification · 1% confidence The document is titled 'DELÅRSRAPPORT Juli-september 2025' (Interim Report July-September 2025) for Immunovia AB. It contains comprehensive financial statements, including the income statement, balance sheet, cash flow statement, and management's discussion and analysis (VD-brev). It covers a period shorter than a full fiscal year (Q3 2025). It is not a mere announcement, as it contains the full financial data and audit review report. Q3 2025
2025-11-26 Swedish
Interim / Quarterly Report 2025
Interim / Quarterly Report Classification · 1% confidence The document is an 'Interim Report' for the period July-September 2025. It contains comprehensive financial statements (income statement, balance sheet, cash flow), management commentary, and an auditor's review report. It is not an announcement of a report, but the report itself, and it covers a period shorter than a full fiscal year, fitting the definition of an Interim/Quarterly Report (IR). Q3 2025
2025-11-26 English
Major Shareholding Notification 2025
Major Shareholding Notification Classification · 1% confidence The document is a 'flaggningsmeddelande' (flagging notification) from the Swedish Financial Supervisory Authority (Finansinspektionen). It details a change in shareholding for Immunovia AB, where Avanza Bank Holding AB has crossed a 5% threshold due to a new share issue. This is a standard major shareholding notification, which corresponds to the 'Major Shareholding Notification' category.
2025-11-13 Swedish
Immunovia genomför en riktad nyemission av aktier till garanter i samband med den genomförda företrädesemissionen
Share Issue/Capital Change Classification · 1% confidence The document is a press release from Immunovia AB announcing a 'directed new share issue' (riktad nyemission) to guarantors as compensation for a previous rights issue. It details the number of shares issued, the subscription price, the rationale for the deviation from shareholders' preferential rights, and the resulting dilution. This falls under the category of share issuance and capital changes.
2025-10-29 Swedish

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.